当前位置:首页 - 行情中心 - 奥泰生物(688606) - 财务分析 - 现金流量表

奥泰生物

(688606)

  

流通市值:34.59亿  总市值:34.59亿
流通股本:7565.44万   总股本:7565.44万

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金409,281,237.77200,842,985.18890,215,461.66603,168,086.39
  收到的税费返还30,042,818.555,110.3426,112,577.4326,364,742.65
  收到其他与经营活动有关的现金25,925,382.422,743,596.9553,240,394.7842,242,732.73
  经营活动现金流入小计465,249,438.74203,591,692.47969,568,433.87671,775,561.77
  购买商品、接受劳务支付的现金228,105,883.42137,837,749.72412,946,825.5271,454,439.49
  支付给职工以及为职工支付的现金89,985,805.8454,791,709.71176,837,435.28146,583,141.28
  支付的各项税费38,392,866.1720,215,209.5553,772,413.6229,385,705.74
  支付其他与经营活动有关的现金55,879,874.3122,928,850.54119,418,769.09109,892,673.27
  经营活动现金流出小计412,364,429.74235,773,519.52762,975,443.49557,315,959.78
  经营活动产生的现金流量净额52,885,009-32,181,827.05206,592,990.38114,459,601.99
二、投资活动产生的现金流量:
  收回投资收到的现金1,198,703,819.47986,714,788.522,077,271,833.571,625,959,726.12
  取得投资收益收到的现金1,184,256.32726,239.243,209,102.479,159,557.79
  处置固定资产、无形资产和其他长期资产收回的现金净额218,294.22212,009.21685,480.186,866,995.11
  收到的其他与投资活动有关的现金--20,000,00020,000,000
  投资活动现金流入小计1,200,106,370.01987,653,036.972,101,166,416.221,661,986,279.02
  购建固定资产、无形资产和其他长期资产支付的现金42,655,558.1522,621,459.18219,096,818.43158,771,492.08
  投资支付的现金157,597,286.84151,428,156.531,732,106,273.631,423,303,120.96
  支付其他与投资活动有关的现金2,766,120-4,288,980-
  投资活动现金流出小计203,018,964.99174,049,615.711,955,492,072.061,582,074,613.04
  投资活动产生的现金流量净额997,087,405.02813,603,421.26145,674,344.1679,911,665.98
三、筹资活动产生的现金流量:
  收到其他与筹资活动有关的现金286,068.78286,068.7820,003,703.7710,357,453.01
  筹资活动现金流入小计286,068.78286,068.7820,003,703.7710,357,453.01
  分配股利、利润或偿付利息支付的现金77,016,414-195,109,725116,798,446.33
  支付其他与筹资活动有关的现金166,115,983.6486,152,015.462,898,998.051,878,977.47
  筹资活动现金流出小计243,132,397.6486,152,015.46198,008,723.05118,677,423.8
  筹资活动产生的现金流量净额-242,846,328.86-85,865,946.68-178,005,019.28-108,319,970.79
四、汇率变动对现金及现金等价物的影响-29,135,405.72-14,518,117.23-11,836,543.94-5,492,523.53
五、现金及现金等价物净增加额777,990,679.44681,037,530.3162,425,771.3280,558,773.65
  加:期初现金及现金等价物余额1,062,762,726.911,066,980,006.91900,336,955.59900,336,955.59
  期末现金及现金等价物余额1,840,753,406.351,748,017,537.211,062,762,726.91980,895,729.24
补充资料:
  净利润50,642,133.11-220,071,907.4-
  资产减值准备1,006,923.8-4,261,937.03-
  固定资产和投资性房地产折旧21,692,512.42-38,026,228.51-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧21,692,512.42-38,026,228.51-
  无形资产摊销1,199,606.14-1,508,573.62-
  长期待摊费用摊销4,358,917.47-5,880,108.09-
  处置固定资产、无形资产和其他长期资产的损失-65,174.37--616,679.63-
  固定资产报废损失16,232.6-21,655.21-
  公允价值变动损失-13,345,598.16--40,611,636.15-
  财务费用25,557,571.4-9,422,355.94-
  投资损失5,519,581.89--335,646.32-
  递延所得税266,849.33-143,986.42-
  其中:递延所得税资产减少266,849.33-155,260.53-
    递延所得税负债增加---11,274.11-
  存货的减少-17,309,479.7--20,551,674.03-
  经营性应收项目的减少-6,836,002.85--77,629,154.9-
  经营性应付项目的增加-27,554,526.2-42,706,748.76-
  其他5,000,192.58-18,510,834.19-
  不涉及现金收支的投资和筹资活动金额其他项目--8,290,714.62-
  现金的期末余额1,840,753,406.35-1,062,762,726.91-
  减:现金的期初余额1,062,762,726.91-900,336,955.59-
  现金及现金等价物的净增加额777,990,679.44-162,425,771.32-
公告日期2026-08-292026-04-202026-04-202025-10-31
审计意见(境内)标准无保留意见
TOP↑